Novo Nordisk Launches Weekly Type 2 Diabetes Treatment in Tunisia

Novo Nordisk announced the official launch of a new weekly injectable treatment for type 2 diabetes in Tunisia on Saturday, May 2, 2026. The therapy is designed to provide a comprehensive approach to metabolic health, offering glycemic control alongside direct protection for the heart, arteries, and kidneys.

The medication will be available in pharmacies across Tunisia starting Wednesday, May 6, 2026. The announcement followed a press conference and the issuance of an official circular to wholesalers to coordinate the rollout of the treatment.

Therapeutic Benefits and Clinical Application

According to Dr. Tayssir Ben Houria, director of public affairs and market access at Novo Nordisk, the treatment represents the first medication available in Tunisia administered via a single weekly injection. This delivery method is intended to address one of the most significant hurdles in diabetes management: patient adherence.

The simplicity of use — a weekly injection instead of daily doses — promotes therapeutic adherence, [which is the] main challenge encountered by doctors in Tunisia.

Dr. Tayssir Ben Houria, Director of Public Affairs and Market Access at Novo Nordisk

Beyond regulating blood sugar levels, the treatment is indicated for patients suffering from obesity related to diabetes, as it contributes to weight loss. Medical officials noted that when used at an early stage of the disease, the therapy can improve a patient’s overall health status and potentially delay the necessity of transitioning to insulin.

The treatment is designed for flexibility in administration, allowing patients to take the injection at any time of the day, regardless of whether it is before or after meals.

Pricing and Availability

The medication is being introduced in three specific dosages: 0.25 mg, 0.5 mg, and 1 mg. Each box contains one injectable pen designed to cover one month of treatment, providing a total of four doses.

The public price for the treatment has been set at 355 Tunisian dinars. To address concerns regarding affordability, Novo Nordisk confirmed that discussions are currently underway with Tunisian health authorities and the Caisse Nationale d’Assurance Maladie (CNAM) to explore reimbursement options and improve patient access.

Public Health Context in Tunisia

The introduction of this therapy comes at a time of rising metabolic health challenges in the region. Reports indicate that approximately 15% of Tunisian citizens suffer from diabetes, contributing to a higher prevalence of non-communicable diseases, particularly cardiovascular and metabolic pathologies, which are leading causes of mortality in the country.

The arrival of the treatment was anticipated by the medical community. On April 11, 2026, Dr. Leïla Abid, head of the cardiology department at Hédi Chaker Hospital in Sfax, noted that such an innovation could significantly improve the quality of life for patients and reduce complications associated with cardiovascular and metabolic diseases.

However, the launch occurs amidst a complex pharmaceutical landscape. Reporting from April 15, 2026, highlighted a contrast between the arrival of high-cost innovative therapies and structural fragilities within the Tunisian health system, including recent stock ruptures of essential medicines reported by the Order of Pharmacists.

Medical experts emphasize that the medication is strictly regulated and will be delivered only upon prescription, ensuring that the therapy is administered under professional medical supervision to manage dosing and monitor patient response.